MXPA04001959A - Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa. - Google Patents

Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa.

Info

Publication number
MXPA04001959A
MXPA04001959A MXPA04001959A MXPA04001959A MXPA04001959A MX PA04001959 A MXPA04001959 A MX PA04001959A MX PA04001959 A MXPA04001959 A MX PA04001959A MX PA04001959 A MXPA04001959 A MX PA04001959A MX PA04001959 A MXPA04001959 A MX PA04001959A
Authority
MX
Mexico
Prior art keywords
dementia
galantamine
formula
topiramate
resulting
Prior art date
Application number
MXPA04001959A
Other languages
English (en)
Spanish (es)
Inventor
Plata-Salaman Carlos
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MXPA04001959A publication Critical patent/MXPA04001959A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA04001959A 2001-08-30 2002-08-28 Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa. MXPA04001959A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31597801P 2001-08-30 2001-08-30
PCT/US2002/027504 WO2003020289A1 (en) 2001-08-30 2002-08-28 Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors

Publications (1)

Publication Number Publication Date
MXPA04001959A true MXPA04001959A (es) 2005-02-17

Family

ID=23226936

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001959A MXPA04001959A (es) 2001-08-30 2002-08-28 Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa.

Country Status (6)

Country Link
US (1) US20030060423A1 (cg-RX-API-DMAC7.html)
EP (1) EP1423127A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005502680A (cg-RX-API-DMAC7.html)
CA (1) CA2459146A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04001959A (cg-RX-API-DMAC7.html)
WO (1) WO2003020289A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
GB0405034D0 (en) * 2004-03-05 2004-04-07 Novartis Ag Organic compounds
CA2559493A1 (en) * 2004-03-12 2005-09-22 Egis Gyogyszergyar Nyrt. Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008066184A1 (en) * 2006-12-01 2008-06-05 Nitto Denko Corporation Method for prevention of coloration in donepezil-containing skin adhesive preparation, and method for reducing the production of donepezil analogue in donepezil-containing skin adhesive preparation
KR101442286B1 (ko) * 2006-12-01 2014-09-22 닛토덴코 가부시키가이샤 경피 흡수 제제
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
BRPI0912099A2 (pt) * 2008-05-30 2015-10-06 Eisai R&D Man Co Ltd preparação percutaneamente absorvível
KR20110011650A (ko) * 2008-05-30 2011-02-08 닛토덴코 가부시키가이샤 도네페질 함유 부착 제제 및 그 포장체
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EA037187B1 (ru) 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2011143721A1 (en) * 2010-05-21 2011-11-24 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating neurodegenerative disorders
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
US12208167B1 (en) * 2024-02-06 2025-01-28 Alpha Cognition Inc. Coated tablets for pH-dependent release of benzgalantamine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
WO1998000124A1 (en) * 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
AU1909700A (en) * 1998-12-03 2000-06-19 Ortho-Mcneil Pharmaceutical, Inc. Topiramate and related derivatives for treating Schizophrenia
JP2003521471A (ja) * 1999-04-08 2003-07-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 慢性神経変性疾患を処置することに有用な抗痙攣薬誘導体
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
EP1187604A4 (en) * 1999-05-28 2004-02-11 Jeffrey Berlant CONNECTIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS FAILURES
AU2001249091A1 (en) * 2000-03-03 2001-09-17 Eisai Co. Ltd. Novel methods using cholinesterase inhibitors
WO2002009694A1 (en) * 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
JP2005501801A (ja) * 2001-02-02 2005-01-20 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド フラクトピラノーススルファメートとエリスロポイエチンを含んで成る神経学的機能不全治療
US6821979B2 (en) * 2002-03-07 2004-11-23 Blanchette Rockefeller Neurosciences Institute Synergistic enhancement of cognitive ability

Also Published As

Publication number Publication date
US20030060423A1 (en) 2003-03-27
JP2005502680A (ja) 2005-01-27
EP1423127A1 (en) 2004-06-02
CA2459146A1 (en) 2003-03-13
WO2003020289A9 (en) 2003-07-10
WO2003020289A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
MXPA04001959A (es) Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa.
US9750746B2 (en) ANAVEX2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection
CA2580619C (en) Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
US9913836B2 (en) Anticholinergic neuroprotective composition and methods
AU782344B2 (en) Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
WO2002009694A1 (en) Anticonvulsant derivatives useful for the treatment of depression
BG106708A (bg) Пиролидинацетамидни производни самостоятелно или в комбинация за лечение на разстройства на цнс
AU2007313911A1 (en) Treatment of Pervasive Developmental Disorders
AU2005219439B2 (en) 1-aminocyclohexane derivatives for the treatment of agitation and other behavioural disorders, especially those associated with alzheimer's disease
WO2009128058A1 (en) Psycho-pharmaceuticals
AU768393B2 (en) Compounds and methods for the treatment of post traumatic stress disorder
MXPA04008259A (es) Co-terapia para el tratamiento de migrana que comprende derivados de un anticonvulsivo y agentes anti-migrana.
US20050090488A1 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
AU2003226753B2 (en) Statin therapy for enhancing cognitive maintenance
AU2002323467A1 (en) Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
JP2005508373A (ja) 抗痙攣剤誘導体およびカリウムを用いる共同療法を含んでなる感覚異常の処置および予防
US20240293435A1 (en) Methods and Compositions for Treating Human Disorders Using D-Cycloserine and a Psychedelic Agent
KR20230163367A (ko) 실행 기능 장애를 치료하기 위한 조합 요법
Hazekamp et al. Clinical Studies With Cannabis and Cannabinoids, 2005-2009
MXPA06009838A (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer’s disease
MXPA99003258A (en) Anticonvulsant derivatives useful in treating neuropathic pain

Legal Events

Date Code Title Description
FA Abandonment or withdrawal